Boaz Weinstein’s Jasper Therapeutics JSPR Stock Holding History

Boaz Weinstein’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-18,786	Closed	-$1.87M	–	533
2021 Q2	$1.87M	Buy	18,786 +5,000	+36%	+$497K	0.05%	298
2021 Q1	$1.37M	Buy	13,786 +1,103	+9%	+$112K	0.04%	270
2020 Q4	$1.27M	Buy	12,683 +9,683	+323%	+$964K	0.05%	106
2020 Q3	$298K	Buy	+3,000	New	+$300K	0.01%	135

Other funds holding JSPR

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPARFS

Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Boaz Weinstein's JSPR Position: Q3 2021 in Review

Boaz Weinstein sold out of Jasper Therapeutics (JSPR) in Q3 2021, closing a stake of 18,786 shares — an estimated $1.87M sold.

Boaz Weinstein first reported a position in JSPR in Q3 2020 and held it in 4 quarters. The position peaked at $1.87M in Q2 2021. 10 funds tracked by Wall St. Rank hold JSPR as of Q3 2021.

Boaz Weinstein reported no remaining Jasper Therapeutics position as of Q3 2021 after selling out during the quarter.
Boaz Weinstein sold 18,786 Jasper Therapeutics shares in Q3 2021, an estimated $1.87M.
Boaz Weinstein first reported a position in Jasper Therapeutics in Q3 2020 and held it in 4 quarters.
Boaz Weinstein's Jasper Therapeutics position peaked at $1.87M in Q2 2021.
10 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q3 2021.

Based on Saba Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.